Relacorilant
Relacorilant is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand name including Lifyorli. Available dosage forms: capsule, powder, kit.
Drug Details
- Generic Name
- Relacorilant
- Brand Names
- Lifyorli
- Application Number
- NDA220641
- Sponsor
- Catalent Pharma Solutions, LLC
- NDC Codes
- 7
- Dosage Forms
- CAPSULE, POWDER, KIT
- Routes
- ORAL
- Active Ingredients
- RELACORILANT
Indications and Usage
1 INDICATIONS AND USAGE LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies ( 14 )] . LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. ( 1 , 14 )